Table of Contents Author Guidelines Submit a Manuscript
International Journal of Endocrinology
Volume 2018, Article ID 6712901, 5 pages
https://doi.org/10.1155/2018/6712901
Research Article

Favorable Effect of Anti-TNF Therapy on Insulin Sensitivity in Nonobese, Nondiabetic Patients with Inflammatory Bowel Disease

1Department of Endocrinology and Diabetes, Hellenic Red Cross Hospital, Athens, Greece
2Department of Gastroenterology, Hellenic Red Cross Hospital, Athens, Greece

Correspondence should be addressed to Stavroula A. Paschou; moc.liamg@uohcsap.a.s

Received 11 August 2017; Accepted 17 January 2018; Published 5 March 2018

Academic Editor: Claudio Casella

Copyright © 2018 Stavroula A. Paschou et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. K. Podolsky, “Inflammatory bowel disease,” The New England Journal of Medicine, vol. 347, no. 6, pp. 417–429, 2002. View at Publisher · View at Google Scholar · View at Scopus
  2. L. C. Silva, L. C. Ortigosa, and G. Benard, “Anti-TNF-α agents in the treatment of immune-mediated inflammatory diseases: mechanisms of action and pitfalls,” Immunotherapy, vol. 2, no. 6, pp. 817–833, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. J. R. Korzenik and D. K. Podolsky, “Evolving knowledge and therapy of inflammatory bowel disease,” Nature Reviews Drug Discovery, vol. 5, no. 3, pp. 197–209, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. P. H. Dessein and B. I. Joffe, “Insulin resistance and impaired beta cell function in rheumatoid arthritis,” Arthritis & Rheumatism, vol. 54, no. 9, pp. 2765–2775, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. D. H. Solomon, T. J. Love, C. Canning, and S. Schneeweiss, “Risk of diabetes among patients with rheumatoid arthritis, psoriatic arthritis and psoriasis,” Annals of the Rheumatic Diseases, vol. 69, no. 12, pp. 2114–2117, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. N. Bregenzer, A. Hartmann, U. Strauch, J. Scholmerich, T. Andus, and L. C. Bollheimer, “Increased insulin resistance and β cell activity in patients with Crohn’s disease,” Inflammatory Bowel Diseases, vol. 12, no. 1, pp. 53–56, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. L. Valentini, E. K. Wirth, U. Schweizer et al., “Circulating adipokines and the protective effects of hyperinsulinemia in inflammatory bowel disease,” Nutrition, vol. 25, no. 2, pp. 172–181, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. G. S. Hotamisligil, “Mechanisms of TNF-α-induced insulin resistance,” Experimental and Clinical Endocrinology & Diabetes, vol. 107, no. 2, pp. 119–125, 1999. View at Publisher · View at Google Scholar
  9. G. S. Hotamisligil, P. Peraldi, A. Budavari, R. Ellis, M. F. White, and B. M. Spiegelman, “IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-α- and obesity-induced insulin resistance,” Science, vol. 271, no. 5249, pp. 665–670, 1996. View at Publisher · View at Google Scholar
  10. D. E. Moller, “Potential role of TNF-α in the pathogenesis of insulin resistance and type 2 diabetes,” Trends in Endocrinology & Metabolism, vol. 11, no. 6, pp. 212–217, 2000. View at Publisher · View at Google Scholar · View at Scopus
  11. K. E. Wellen and G. S. Hotamisligil, “Inflammation, stress, and diabetes,” The Journal of Clinical Investigation, vol. 115, no. 5, pp. 1111–1119, 2005. View at Publisher · View at Google Scholar
  12. M. A. Gonzalez-Gay, C. Gonzalez-Juanatey, T. R. Vazquez-Rodriguez, J. A. Miranda- Filloy, and J. Llorca, “Insulin resistance in rheumatoid arthritis: the impact of the anti-TNF-α therapy,” Annals of the New York Academy of Sciences, vol. 1193, no. 1, pp. 153–159, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. D. N. Kiortsis, A. K. Mavridis, S. Vasakos, S. N. Nikas, and A. A. Drosos, “Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis,” Annals of the Rheumatic Diseases, vol. 64, no. 5, pp. 765-766, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. L. T. Jacobsson, C. Turesson, A. Gülfe et al., “Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis,” The Journal of Rheumatology, vol. 32, pp. 1213–1218, 2005. View at Google Scholar
  15. W. G. Dixon, K. D. Watson, M. Lunt, K. L. Hyrich, A. J. Silman, and D. P. Simmons, “Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor α therapy: results from the British society for rheumatology biologics register,” Arthritis and Rheumatism, vol. 56, no. 9, pp. 2905–2912, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. E. Vassilatou, A. Vryonidou, D. Ioannidis, S. A. Paschou, M. Panagou, and I. Tzavara, “Bilateral adrenal incidentalomas differ from unilateral adrenal incidentalomas in subclinical cortisol hypersecretion but not in potential clinical implications,” European Journal of Endocrinology, vol. 171, no. 1, pp. 37–45, 2014. View at Publisher · View at Google Scholar · View at Scopus
  17. R. H. Straub, “Insulin resistance, selfish brain, and selfish immune system: an evolutionarily positively selected program used in chronic inflammatory diseases,” Arthritis Research & Therapy, vol. 13, Supplement 2, article S4, no. 16, 2014. View at Publisher · View at Google Scholar · View at Scopus
  18. L. S. Tam, B. Tomlinson, T. T. Chu, T. K. Li, and E. K. Li, “Impact of TNF inhibition on insulin resistance and lipids levels in patients with rheumatoid arthritis,” Clinical Rheumatology, vol. 26, no. 9, pp. 1495–1498, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Stavropoulos-Kalinoglou, G. Metsios, V. Panoulas, P. Nightingale, Y. Koutedakis, and G. Kitas, “Anti-tumour necrosis factor alpha therapy improves insulin sensitivity in normal-weight but not in obese patients with rheumatoid arthritis,” Arthritis Research & Therapy, vol. 14, no. 4, article R160, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. A. N. Burska, R. Sakthiswary, and N. Sattar, “Effects of tumour necrosis factor antagonists on insulin sensitivity/resistance in rheumatoid arthritis: a systematic review and meta-analysis,” PLoS One, vol. 10, no. 6, article e0128889, 2015. View at Publisher · View at Google Scholar · View at Scopus
  21. I. Stagakis, G. Bertsias, S. Karvounaris et al., “Anti-tumor necrosis factor therapy improves insulin resistance, beta cell function and insulin signaling in active rheumatoid arthritis patients with high insulin resistance,” Arthritis Research & Therapy, vol. 14, no. 3, article R141, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. M. Gupta-Ganguli, K. Cox, B. Means, I. Gerling, and S. S. Solomon, “Does therapy with anti–TNF-α improve glucose tolerance and control in patients with type 2 diabetes?” Diabetes Care, vol. 34, no. 7, article e121, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. E. Capristo, G. Mingrone, G. Addolorato, A. V. Greco, and G. Gasbarrini, “Glucose metabolism and insulin sensitivity in inactive inflammatory bowel disease,” Alimentary Pharmacology and Therapeutics, vol. 13, no. 2, pp. 209–217, 1999. View at Publisher · View at Google Scholar · View at Scopus
  24. I. E. Koutroubakis, P. Oustamanolakis, N. Malliaraki et al., “Effects of tumor necrosis factor alpha inhibition with infliximab on lipid levels and insulin resistance in patients with inflammatory bowel disease,” European Journal of Gastroenterology & Hepatology, vol. 21, pp. 283–288, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. A. Rosenvinge, R. Krogh-Madsen, B. Baslund, and B. K. Pedersen, “Insulin resistance in patients with rheumatoid arthritis: effect of anti-TNFα therapy,” Scandinavian Journal of Rheumatology, vol. 36, no. 2, pp. 91–96, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. Y. Shoenfeld, R. Gerli, A. Doria et al., “Accelerated atherosclerosis in autoimmune rheumatic diseases,” Circulation, vol. 112, pp. 3337–3347, 2005. View at Publisher · View at Google Scholar · View at Scopus
  27. J. A. Avina-Zubieta, H. K. Choi, M. Sadatsafavi, M. Etminan, J. M. Esdaile, and D. Lacaille, “Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies,” Arthritis & Rheumatism, vol. 59, no. 12, pp. 1690–1697, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. L. Eder and D. D. Gladman, “Atherosclerosis in psoriatic disease: latest evidence and clinical implications,” Therapeutic Advances in Musculoskeletal Disease, vol. 7, no. 5, pp. 187–195, 2015. View at Publisher · View at Google Scholar · View at Scopus
  29. A. Dregan, J. Charlton, P. Chowienczyk, and M. C. Gulliford, “Chronic inflammatory disorders and risk of type 2 diabetes mellitus, coronary heart disease, and stroke: a population-based cohort study,” Circulation, vol. 130, no. 10, pp. 837–844, 2014. View at Publisher · View at Google Scholar · View at Scopus
  30. A. Papa, A. Santoliquido, S. Danese et al., “Increased carotid intima–media thickness in patients with inflammatory bowel disease,” Alimentary Pharmacology & Therapeutics, vol. 22, pp. 839–846, 2005. View at Publisher · View at Google Scholar · View at Scopus
  31. N. Dagli, O. K. Poyrazoglu, A. F. Dagli et al., “Is inflammatory bowel disease a risk factor for early atherosclerosis?” Angiology, vol. 61, no. 2, pp. 198–204, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. J. Dong, Y. Chen, Y. Tang et al., “Body mass index is associated with inflammatory bowel disease: a systematic review and meta-analysis,” PLoS One, vol. 10, no. 12, article e0144872, 2015. View at Publisher · View at Google Scholar · View at Scopus
  33. D. D. Mijac, G. L. Janković, J. Jorga, and M. N. Krstić, “Nutritional status in patients with active inflammatory bowel disease: prevalence of malnutrition and methods for routine nutritional assessment,” European Journal of Internal Medicine, vol. 21, no. 4, pp. 315–319, 2010. View at Publisher · View at Google Scholar · View at Scopus
  34. C. N. Bernstein, M. Fried, J. H. Krabshuis et al., “World gastroenterology organization practice guidelines for the diagnosis and management of IBD in 2010,” Inflammatory Bowel Diseases, vol. 16, pp. 112–124, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. A. Agouridis, M. Elisaf, and H. Milionis, “An overview of lipid abnormalities in patients with inflammatory bowel disease,” Annals of Gastroenterology, vol. 24, pp. 181–187, 2011. View at Google Scholar
  36. A. M. van Sijl, M. J. Peters, D. L. Knol et al., “The effect of TNF-alpha blocking therapy on lipid levels in rheumatoid arthritis: a meta-analysis,” Seminars in Arthritis & Rheumatism, vol. 41, no. 3, pp. 393–400, 2011. View at Publisher · View at Google Scholar · View at Scopus
  37. M. J. Kraakman, D. Dragoljevic, H. L. Kammoun, and A. J. Murphy, “Is the risk of cardiovascular disease altered with anti-inflammatory therapies? Insights from rheumatoid arthritis,” Clinical & Translational Immunology, vol. 5, no. 5, article e84, 2016. View at Publisher · View at Google Scholar
  38. C. Roubille, V. Richer, T. Starnino et al., “The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis,” Annals of the Rheumatic Diseases, vol. 74, no. 3, pp. 480–489, 2015. View at Publisher · View at Google Scholar · View at Scopus
  39. M. Saghizadeh, J. M. Ong, W. T. Garvey, R. R. Henry, and P. A. Kern, “The expression of TNF alpha by human muscle. Relationship to insulin resistance,” The Journal of Clinical Investigation, vol. 97, no. 4, pp. 1111–1116, 1996. View at Publisher · View at Google Scholar
  40. S. S. Solomon, O. Odunusi, D. Carrigan et al., “TNF-α inhibits insulin action in liver and adipose tissue: a model of metabolic syndrome,” Hormone and Metabolic Research, vol. 42, pp. 115–121, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. T. Van der Poll, J. A. Romijn, E. Endert, J. J. Borm, H. R. Buller, and H. P. Sauerwein, “Tumor necrosis factor mimics the metabolic response to acute infection in healthy humans,” The American Journal of Physiology-Endocrinology and Metabolism, vol. 261, no. 4, Part 1, pp. E457–E465, 1991. View at Publisher · View at Google Scholar